Máj- és epeúti rák: vizsgálatok itt: Kína
621 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisNot yet taking people in KínaY-90 SIRT for Unresectable HCC Larger Than 7cm
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 33
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT06707233 - No phaseTaking peopleProspective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 500
- Run by
- Sun Yat-sen University
See details and how to joinNCT06788353 - 2. fázisTaking peoplePhase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE
- Where
- Nanjing, Xuzhou, Yancheng
- Életkor
- 18 év to 75 év
- People
- 122
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06607276 - 3. fázisNot yet taking people in KínaA Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
- Where
- Anyang, Bengbu, Guangzhou, Lanzhou, Lishui, Luoyang, Nanjing, Shanghai, Tianjin, Zhengzhou
- Életkor
- 18 év to 80 év
- People
- 228
- Run by
- InnoBM Pharmaceuticals Co., Ltd.
See details and how to joinNCT06779461 - No phaseTaking peopleTIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 42
- Run by
- Sun Yat-sen University
See details and how to joinNCT06622031 - 2. fázisTaking peopleExploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
- Where
- Fuyang, Hefei
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT06664021 - 2. fázisTaking peopleTislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 80
- Run by
- Sun Yat-sen University
See details and how to joinNCT04615143 - 2. fázisTaking peopleStereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 130
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06766643 - 2. fázisTaking peopleClinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
- Where
- Nanjing
- Életkor
- 18 év to 80 év
- People
- 276
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06762782 - 3. fázisTaking peopleCamrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 130
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT05613478 - 2. fázisTaking peopleFruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 36
- Run by
- Sun Yat-sen University
See details and how to joinNCT06446154 - No phaseTaking peopleCirculating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 50
- Run by
- Tongji Hospital
See details and how to joinNCT06653062 - No phaseTaking peopleCirculating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence Surveillance
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 50
- Run by
- Tongji Hospital
See details and how to joinNCT06653127 - No phaseNot yet taking people in KínaEffect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 84
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06749678 - 1. fázisTaking peopleMts105 for Advanced Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 14
- Run by
- Shen Lin
See details and how to joinNCT06689540 - No phaseTaking peopleThe Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Ruijin Hospital
See details and how to joinNCT06746194 - 2. fázisTaking peopleClinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 33
- Run by
- CNBG-Virogin Biotech (Shanghai) Ltd.
See details and how to joinNCT06746480 - No phaseTaking peopleStudy on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
- Where
- Chenzhou, Guangzhou, Hengyang
- Életkor
- 18 év to 65 év
- People
- 400
- Run by
- Xiangya Hospital of Central South University
See details and how to joinNCT06746701 - 1. fázisTaking peopleOH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 12
- Run by
- Binhui Biopharmaceutical Co., Ltd.
See details and how to joinNCT05698459 - 2. fázisTaking peoplePD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
- Where
- Chengdu
- Életkor
- 18 év to 75 év
- People
- 36
- Run by
- West China Hospital
See details and how to joinNCT06742424 - 2. fázisTaking peopleA Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 117
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06349980 - 2/3. fázisNot yet taking people in KínaSBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 398
- Run by
- Sun Yat-sen University
See details and how to joinNCT06739317 - No phaseTaking peopleRecurrent Liver Cancer: Reconceptualization and Reevaluation
- Where
- Nanjing
- Életkor
- 18 év to 75 év
- People
- 300
- Run by
- Nanjing Medical University
See details and how to joinNCT06430983 - 2. fázisNot yet taking people in KínaA Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 120
- Run by
- Tasly Biopharmaceuticals Co., Ltd.
See details and how to joinNCT06724263 - 2. fázisTaking peopleToripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 70
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06721286